RxDoctor Payments Data

Michael Bradley, MD

Orthopaedic Surgery · Wakefield, RINPI 1083668883

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (42.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Arthrex accounts for 63.2% of it on its own, with 19 other manufacturers making up the rest. Among orthopaedic surgery clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,361,606in general payments, 2019–2025

Across 607 payments — averaging $2243.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$860K
  • FX Shoulder Solutions, Inc$183K
  • Corin USA$98K
  • Omnilife Science, Inc$80K
  • Encore Medical, LP$59K
  • Intellijoint Surgical Inc.$59K
  • plus $23K from 14 others
$176,957in research payments, 2019–2025

Across 27 payments — averaging $6553.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • FX Shoulder Solutions, Inc$154K
  • Illuminoss Medical, Inc.$12K
  • Arthrex$11K
$188,993in ownership & investment interests, 2019–2025

Across 3 payments — averaging $62,998 each. An ownership or investment interest held by the physician or an immediate family member.

  • Omnilife Science, Inc$164K
  • Intellijoint Surgical Inc.$25K

What the payments were for

  • Royalty or licence$583,41643%
  • Consulting fees$371,40927%
  • Speaking & faculty fees$311,03923%
  • Travel & lodging$84,4006%
  • Food & beverage$11,2281%
  • Gifts$1140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,361,606 in reported general payments places this provider in the 95th percentile of 124 orthopaedic surgery providers in Rhode Island.

See all orthopaedic surgery providers in Rhode Island

Medicare billing

Part B allowed, 2024
$271,844
Medicare patients
318
Services billed
2,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl318$2,213
Diclofenac Sodium54$1,401
Meloxicam358$968
Tranexamic Acid163$810
Ibuprofen36$455
Gabapentin67$367
Naproxen18$225
Omeprazole158$163
Mupirocin22$137
Cyclobenzaprine Hcl11$37
Amoxicillin22$30

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Wakefield

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →